Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.50 |
| ▸ | FNTB | P49356 | 6/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656453 | 0.92 | FNTA (0.59) | FNTAFNTBPGGT1B | |
| SCHEMBL5659774 | 0.89 | FNTA (0.52) | FNTAFNTBPGGT1B | |
| SCHEMBL5657074 | 0.80 | FNTA (0.67) | FNTAFNTBPGGT1B | |
| SCHEMBL14588487 | 0.78 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL14588483 | 0.77 | FNTA (0.52) | FNTAFNTBPGGT1BMAPT | |
| SCHEMBL5655411 | 0.76 | FNTA (0.46) | FNTAFNTBPGGT1B | |
| SCHEMBL5659913 | 0.75 | FNTA (0.70) | FNTAFNTBPGGT1BTSHR | |
| SCHEMBL5016825 | 0.75 | FNTA (0.61) | FNTAFNTBPGGT1B | |
| SCHEMBL6791445 | 0.74 | FNTA (0.46) | FNTAFNTBPGGT1B | |
| SCHEMBL5543925 | 0.74 | FNTA (0.60) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173040-B2 | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-06 | — | — | US | claimed |
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | JANSSEN-CILAG S.A. (FR) | 2004-03-11 | — | — | US | claimed |
| US-7173040-B2 | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | JANSSEN-CILAG S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | FNTB, FNTA, CYP7A1 | FNTA 2/4885FNTB 1/4885PGGT1B 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.